Details der Publikation - A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

Background To reveal roles of reactive oxygen species (ROS) status in chemotherapy resistance and to develop a ROS scoring system for prognosis prediction in ovarian cancer. Methods We tested the sensitizing effects of ROS elevating drugs to cisplatin (cDDP) in ovarian cancer both in vitro and in vivo. A ROS scoring system was developed using The Cancer Genome Atlas (TCGA) database of ovarian cancer. The associations between ROS scores and overall survival (OS) were analyzed in TCGA, Tothill dataset, and our in-house dataset (TJ dataset). Results ROS-inducing drugs increased cisplatin-induced ovarian cancer cell injury in vitro and in vivo. ROS scoring system was established using 25 ROS-related genes. Patients were divided into low (scores 0–12) and high (scores 13–25) score groups. Improved patient survival was associated with higher scores (TCGA dataset hazard ratio (HR) = 0.43, P < 0.001; Tothill dataset HR = 0.65, P = 0.022; TJ dataset HR = 0.40, P = 0.003). The score was also significantly associated with OS in multiple datasets (TCGA dataset $ r^{2} $ = 0.574, P = 0.032; Thothill dataset $ r^{2} $ = 0.266, P = 0.049; TJ dataset $ r^{2} $ = 0.632, P = 0.001) and with cisplatin sensitivity in ovarian cancer cell lines ($ r^{2} $ = 0.799, P = 0.016) when used as a continuous variable. The scoring system showed better prognostic performance than other clinical factors by receiver operating characteristic (ROC) curves (TCGA dataset area under the curve (AUC) = 0.71 v.s. 0.65, Tothill dataset AUC = 0.73 v.s. 0.67, TJ dataset AUC = 0.74 v.s. 0.66). Conclusions ROS status is associated with chemotherapy resistance. ROS score system might be a prognostic biomarker in predicting the survival benefit from ovarian cancer patients..

Medienart:	E-Artikel

Erscheinungsjahr:	2019
Erschienen:	2019

Enthalten in:	Zur Gesamtaufnahme - volume:19
Enthalten in:	BMC cancer - 19(2019), 1 vom: 08. Nov.

Sprache:	Englisch

Beteiligte Personen:	Sun, Chaoyang [VerfasserIn] Guo, Ensong [VerfasserIn] Zhou, Bo [VerfasserIn] Shan, Wanying [VerfasserIn] Huang, Jia [VerfasserIn] Weng, Danhui [VerfasserIn] Wu, Peng [VerfasserIn] Wang, Changyu [VerfasserIn] Wang, Shixuan [VerfasserIn] Zhang, Wei [VerfasserIn] Gao, Qinglei [VerfasserIn] Xu, Xiaoyan [VerfasserIn] Wang, Beibei [VerfasserIn] Hu, Junbo [VerfasserIn] Ma, Ding [VerfasserIn] Chen, Gang [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	Prognosis ROS Scoring system Serous ovarian Cancer

Anmerkungen:	© The Author(s). 2020

doi:	10.1186/s12885-019-6288-7

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC210040735X

Internformat


LEADER	01000caa a22002652 4500
001	OLC210040735X
003	DE-627
005	20230504122710.0
007	cr uuu---uuuuu
008	230401s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s12885-019-6288-7 \|2 doi
035			\|a (DE-627)OLC210040735X
035			\|a (DE-He213)s12885-019-6288-7-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
100	1		\|a Sun, Chaoyang \|e verfasserin \|4 aut
245	1	0	\|a A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s). 2020
520			\|a Background To reveal roles of reactive oxygen species (ROS) status in chemotherapy resistance and to develop a ROS scoring system for prognosis prediction in ovarian cancer. Methods We tested the sensitizing effects of ROS elevating drugs to cisplatin (cDDP) in ovarian cancer both in vitro and in vivo. A ROS scoring system was developed using The Cancer Genome Atlas (TCGA) database of ovarian cancer. The associations between ROS scores and overall survival (OS) were analyzed in TCGA, Tothill dataset, and our in-house dataset (TJ dataset). Results ROS-inducing drugs increased cisplatin-induced ovarian cancer cell injury in vitro and in vivo. ROS scoring system was established using 25 ROS-related genes. Patients were divided into low (scores 0–12) and high (scores 13–25) score groups. Improved patient survival was associated with higher scores (TCGA dataset hazard ratio (HR) = 0.43, P < 0.001; Tothill dataset HR = 0.65, P = 0.022; TJ dataset HR = 0.40, P = 0.003). The score was also significantly associated with OS in multiple datasets (TCGA dataset $ r^{2} $ = 0.574, P = 0.032; Thothill dataset $ r^{2} $ = 0.266, P = 0.049; TJ dataset $ r^{2} $ = 0.632, P = 0.001) and with cisplatin sensitivity in ovarian cancer cell lines ($ r^{2} $ = 0.799, P = 0.016) when used as a continuous variable. The scoring system showed better prognostic performance than other clinical factors by receiver operating characteristic (ROC) curves (TCGA dataset area under the curve (AUC) = 0.71 v.s. 0.65, Tothill dataset AUC = 0.73 v.s. 0.67, TJ dataset AUC = 0.74 v.s. 0.66). Conclusions ROS status is associated with chemotherapy resistance. ROS score system might be a prognostic biomarker in predicting the survival benefit from ovarian cancer patients.
650		4	\|a Serous ovarian Cancer
650		4	\|a ROS
650		4	\|a Scoring system
650		4	\|a Prognosis
700	1		\|a Guo, Ensong \|4 aut
700	1		\|a Zhou, Bo \|4 aut
700	1		\|a Shan, Wanying \|4 aut
700	1		\|a Huang, Jia \|4 aut
700	1		\|a Weng, Danhui \|4 aut
700	1		\|a Wu, Peng \|4 aut
700	1		\|a Wang, Changyu \|4 aut
700	1		\|a Wang, Shixuan \|4 aut
700	1		\|a Zhang, Wei \|4 aut
700	1		\|a Gao, Qinglei \|4 aut
700	1		\|a Xu, Xiaoyan \|4 aut
700	1		\|a Wang, Beibei \|4 aut
700	1		\|a Hu, Junbo \|4 aut
700	1		\|a Ma, Ding \|4 aut
700	1		\|a Chen, Gang \|0 (orcid)0000-0002-8320-6594 \|4 aut
773	0	8	\|i Enthalten in \|t BMC cancer \|d BioMed Central, 2001 \|g 19(2019), 1 vom: 08. Nov. \|h Online-Ressource \|w (DE-627)326643710 \|w (DE-600)2041352-X \|w (DE-576)107014645 \|x 1471-2407 \|7 nnns
773	1	8	\|g volume:19 \|g year:2019 \|g number:1 \|g day:08 \|g month:11
856	4	0	\|u https://dx.doi.org/10.1186/s12885-019-6288-7 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 19 \|j 2019 \|e 1 \|b 08 \|c 11

A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände